Clinical use of flow cytometric (FCM) DNA analysis requires effective quality controls. Thirty-two laboratories with various degrees of FCM experience participated in the first phase of a quality control program organized by the Association Franqaise de Cytometrie. All received diskettes containing
Quality control for evaluation of the S-phase fraction by flow cytometry: A multicentric study
β Scribed by Rosella Silvestrini
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 521 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
β¦ Synopsis
Flow cytometric measurement of the S-phase fraction (FCM-Sl may be clinically useful in human cancers to identify high-risk patients. However, its clinical application requires a methodologic standardization, a high feasibility, and the reproducibility of results within the same and among different institutions. The interlaboratory quality control program for FCM-S determination (promoted by the Italian Society of Basic and Applied Cell Kinetics) was carried out on DNA diploid and aneuploid cell lines and human breast cancers. FCM-S was quantified by using four mathematical models characterized by different rationales and differences in the degree and shape of background subtraction functions. A satisfactory agreement in FCM-S values among different institutions was observed for cell lines. In human breast cancers, a high reproducibility of FCM-S estimates obtained by the different institutions was observed by using the same model. Conversely, different models gave different FCM-S estimates. lntermodel differences were more evident in aneuploid than in diploid tumors. These findings could explain the contrasting results on the prognostic role of FCM-S in clinically comparable series of breast cancers and should be considered in future efforts to define the optimal and most reproducible mathematical approach to quantify cells in the S-phase.
π SIMILAR VOLUMES